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patient-reported HRQoL. METHODS: We compared baseline
Short Form (SF)-36 scores for individuals with ITP who enrolled
in one of two double-blind, randomized clinical trials for the
treatment of ITP [one group was refractory to splenectomy
(n = 58) and the other had no splenectomy (n = 60)] to general
populations in Canada (n = 9408) and the US (n = 2474). We
also compared ITP-speciﬁc HRQoL burden using the ITP-Patient
Assessment Questionnaire (PAQ) across platelet count categories
(<10 ¥ 109/L vs. 10 to 49 ¥ 109/L). ANOVA tests were used to
compare age and sex-adjusted means across samples. RESULTS:
The mean age of the ITP patients was 53.3  16.2 years, and the
majority (64%) was female. SF-36 scores of ITP patients were
signiﬁcantly (p < 0.0001) worse than those from the Canadian
and US general population for each scale and summary score.
The largest differences were found for physical functioning (67.2
vs. 85.8 and 80.8); role functioning-physical (42.3 vs. 82.1 and
77.0); general health (49.4 vs. 77.0 and 69.9); vitality (40.4 vs.
65.8 and 60.0), and role functioning-emotional (60.5 vs. 84.0
and 80.1). In addition to statistical signiﬁcance, these differences
were clinically meaningful. ITP patients with lower platelet
counts also had worse SF-36 and ITP-PAQ scores, particularly
for symptoms (50.8 vs. 67.8; p < 0.001); fear (65.0 vs. 78.9;
p < 0.05), and social activity scales (59.6 vs. 75.5; p < 0.05) of
the ITP-PAQ. CONCLUSION: ITP was found to impact both
physical and psychological aspects of HRQoL.
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OBJECTIVE: Radiation Therapy Oncology Group (RTOG)
study 0215 was a placebo-controlled, double-blind, cross-over
trial of sildenaﬁl given after radiotherapy and neoadjuvant/
concurrent short-term androgen suppression. Sildenaﬁl improved
erectile function amongst participants. We now report on the
study goal to investigate the effect of sildenaﬁl on marital
and sexual adjustment for participants and their partners.
METHODS: RTOG 0215 closed before meeting its desired
accrual goal with enrollment of 111 eligible patients (72
married). Twenty-four patients (mean age: 72.6  6.8 y) and
their married partners (mean marriage duration: 37.2  16.3 y)
completed the self-report assessments of erectile function and of
marital and sexual adjustment using the validated measures of
the Locke’s Marital Adjustment Test (LMAT) and the Sexual
Adjustment Questionnaire (SAQ). Statistical differences in and
correlations between the change in LMAT and SAQ scores were
tested for signiﬁcance from placebo to sildenaﬁl. RESULTS:
There was no signiﬁcant change in LMAT scores for either
patients (p = 0.37) or partners (p = 0.35). The change in patient
SAQ score was statistically signiﬁcant, but not clinically mean-
ingful (D = 2.58, p = 0.02), while partners reported a smaller
change in SAQ score (D = 1.47, p = 0.47). The correlations
between patient and partner LMAT change scores (r = 0.40,
p = 0.09) and SAQ change scores (r = 0.15, p = 0.48) were non-
signiﬁcant. Patient LMAT and SAQ change scores (r = 0.38,
p = 0.08) were not signiﬁcantly correlated. However, the partner
LMAT and SAQ change scores (r = 0.45, p = 0.04) were signiﬁ-
cantly correlated. CONCLUSION: Erectile dysfunction (ED)
affects, and is affected by, the patient, their partner and the
relationship. ED treatment appears to signiﬁcantly inﬂuence
female partner sexual adjustment and marital adjustment. These
results are tentative and should be considered as an exploratory
basis for a larger clinical trial. The small sample size may have
precluded detection of important other endpoints, which should
not be excluded from future investigations.
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OBJECTIVE: To systematically identify utility weights for health
states in breast cancer. METHODS: Searches were performed of
electronic databases (PubMed, EMBASE and the Cochrane
Library, including DARE, NHS EED and HTA databases) and
internet resources for the period 1990 to date. Sources poten-
tially containing relevant information were retrieved and
reviewed. RESULTS: Fifty-nine studies were identiﬁed as poten-
tially containing utility weights for breast cancer health states.
These were assessed for methodological compliance with the
NICE reference case, leading to the exclusion of 50 non-
compliant studies. Within the remaining nine studies there was
wide variability between both alternative NICE compliant esti-
mates for similar health states, and the health states deﬁned. In
some cases estimates for poor health states (for example meta-
static disease) were higher than those for good health states (for
example remission). For some health states (notably terminal
disease) there are no estimates available based on NICE recom-
mendations. CONCLUSION: A review of utility weights for
breast cancer health states has revealed high levels of uncertainty
within the identiﬁed estimates. Despite the quantity of informa-
tion available there is no universally accepted set of health states
covering the whole of the disease pathway for breast cancer,
which has lead to the development of numerous utility estimates
for numerous health states. The review also highlighted that the
majority of studies undertaken (85% of potential studies identi-
ﬁed) do not conform to the methodological standards stipulated
in the NICE reference case. This is predominantly due to the
elicitation method used. For some health states there are no
estimates available based on these recommendations. It is a dif-
ﬁcult task to identify a coherent set of health state utilities cov-
ering the entire disease pathway in breast cancer using previously
published data and which conform to NICE standards.
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OBJECTIVE:Cancer clinical trials frequently incorporate quality
of life (QL) measures, but rarely patient utility and resource
utilization. Cost utility evaluations of novel cancer therapies
remain challenging. Here we explore the correlation between
QL data from the EORTC QLQ-C30 with the EQ5D, for which
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